Try our beta test site
1 study found for:    NCT00109161
Show Display Options
Rank Status Study
1 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)

Study has passed its completion date and status has not been verified in more than two years.